Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/40526
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | |
dc.contributor.author | LEBKUCHEN, Adriana | |
dc.contributor.author | FREITAS, Lunara S. | |
dc.contributor.author | CARDOZO, Karina H. M. | |
dc.contributor.author | DRAGER, Luciano F. | |
dc.date.accessioned | 2021-06-17T13:50:27Z | - |
dc.date.available | 2021-06-17T13:50:27Z | - |
dc.date.issued | 2021 | |
dc.identifier.citation | TRENDS IN CARDIOVASCULAR MEDICINE, v.31, n.4, p.242-249, 2021 | |
dc.identifier.issn | 1050-1738 | |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/40526 | - |
dc.description.abstract | Several challenges have been noted in the pursuit of a comprehensive knowledge base about the impact of OSA including: 1) the precise mechanisms by which OSA causes metabolic and cardiovascular consequences are not clear, which limits our current ability to address potential targets in OSA; 2) several patients with OSA, even with severe forms, present with no or mild daytime symptoms. Beyond the obvious challenges for obtaining good adherence for conventional OSA treatments, there is evidence that symptomatic vs. asymptomatic patients with OSA do not necessarily have the same metabolic and cardiovascular outcomes; and 3) the cardiovascular response to OSA treatment may vary even in those patients with good adherence. In this scenario, there is an obvious need to develop biomarkers in the OSA research area. This review focuses on describing the advances that have occurred so far in exploring potential OSA biomarkers with clear emphasis for the cardiovascular risk. Particular attention will be devoted to discuss molecular biomarkers including the potential role of microRNAs, proteomics and metabolomics. We also discuss the major challenges and perspectives in this growing research field. Obstructive sleep apnea (OSA) is a common clinical condition associated with increased cardiovascular morbidity and mortality. Recent evidence from clinical studies and animal models suggest that OSA can promote cardiovascular disease by inducing autonomic, hemodynamic, inflammatory and metabolic dysregulation. However, most of the evidence addressing hard endpoints in humans is derived from observational studies. Several challenges have been noted in the pursuit of a comprehensive knowledge base about the impact of OSA including: 1) the precise mechanisms by which OSA causes metabolic and cardiovascular consequences are not clear, which limits our current ability to address potential targets in OSA; 2) several patients with OSA, even with severe forms, present with no or mild daytime symptoms. Beyond the obvious challenges for obtaining good adherence for conventional OSA treatments, there is evidence that symptomatic vs. asymptomatic patients with OSA do not necessarily have the same metabolic and cardiovascular outcomes; and 3) the cardiovascular response to OSA treatment may vary even in those patients with good adherence. In this scenario, there is an obvious need to develop biomarkers in the OSA research area. This review focuses on describing the advances that have occurred so far in exploring potential OSA biomarkers with clear emphasis for the cardiovascular risk. Particular attention will be devoted to discuss molecular biomarkers including the potential role of microRNAs, proteomics and metabolomics. We also discuss the major challenges and perspectives in this growing research field. | eng |
dc.language.iso | eng | |
dc.publisher | ELSEVIER SCIENCE LONDON | eng |
dc.relation.ispartof | Trends in Cardiovascular Medicine | |
dc.rights | restrictedAccess | eng |
dc.subject | Biomarkers | eng |
dc.subject | Cardiovascular disease | eng |
dc.subject | Prognosis | eng |
dc.subject | Sleep apnea | eng |
dc.title | Advances and challenges in pursuing biomarkers for obstructive sleep apnea: Implications for the cardiovascular risk ? | eng |
dc.type | article | eng |
dc.rights.holder | Copyright ELSEVIER SCIENCE LONDON | eng |
dc.identifier.doi | 10.1016/j.tcm.2020.04.003 | |
dc.identifier.pmid | 32413393 | |
dc.subject.wos | Cardiac & Cardiovascular Systems | eng |
dc.type.category | original article | eng |
dc.type.version | publishedVersion | eng |
hcfmusp.author.external | LEBKUCHEN, Adriana:Fleury Grp, Sao Paulo, Brazil | |
hcfmusp.author.external | FREITAS, Lunara S.:Univ Sao Paulo, Med Sch, Heart Inst InCor, Hypertens Unit, Ave Dr Eneas de Carvalho Aguiar 44, BR-05403900 Sao Paulo, Brazil | |
hcfmusp.author.external | CARDOZO, Karina H. M.:Fleury Grp, Sao Paulo, Brazil | |
hcfmusp.description.beginpage | 242 | |
hcfmusp.description.endpage | 249 | |
hcfmusp.description.issue | 4 | |
hcfmusp.description.volume | 31 | |
hcfmusp.origem | WOS | |
hcfmusp.origem.id | WOS:000635769900008 | |
hcfmusp.origem.id | 2-s2.0-85085945128 | |
hcfmusp.publisher.city | LONDON | eng |
hcfmusp.publisher.country | ENGLAND | eng |
hcfmusp.relation.reference | Abbassi-Ghadi N, 2013, EUR J CANCER, V49, P3625, DOI 10.1016/j.ejca.2013.07.004 | eng |
hcfmusp.relation.reference | Amann A, 2005, BREATH ANALYSIS: FOR CLINICAL DIAGNOSIS AND ATHERAPEUTIC MONITORING, P305, DOI 10.1142/9789812701954_0020 | eng |
hcfmusp.relation.reference | Anderson NL, 2000, CURR OPIN BIOTECH, V11, P408, DOI 10.1016/S0958-1669(00)00118-X | eng |
hcfmusp.relation.reference | [Anonymous], 2006, AM J RESP CRIT CARE, V173, P811, DOI 10.1164/rrcm.2061014 | eng |
hcfmusp.relation.reference | Archontogeorgis K, 2014, PULM MED, V2014, DOI 10.1155/2014/930535 | eng |
hcfmusp.relation.reference | Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989 | eng |
hcfmusp.relation.reference | Ayas NT, 2019, LUNG, V197, P459, DOI 10.1007/s00408-019-00237-0 | eng |
hcfmusp.relation.reference | Azarbarzin A, 2019, EUR HEART J, V40, P1149, DOI 10.1093/eurheartj/ehy624 | eng |
hcfmusp.relation.reference | Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031 | eng |
hcfmusp.relation.reference | Barbe F, 2001, ANN INTERN MED, V134, P1015, DOI 10.7326/0003-4819-134-11-200106050-00007 | eng |
hcfmusp.relation.reference | Baron KG, 2018, SLEEP MED REV, V40, P151, DOI 10.1016/j.smrv.2017.12.002 | eng |
hcfmusp.relation.reference | Bayrakli I, 2016, BIOMED CHROMATOGR, V30, P1890, DOI 10.1002/bmc.3757 | eng |
hcfmusp.relation.reference | Benjafield AV, 2019, LANCET RESP MED, V7, P687, DOI 10.1016/S2213-2600(19)30198-5 | eng |
hcfmusp.relation.reference | Bratel T, 1999, RESP MED, V93, P1, DOI 10.1016/S0954-6111(99)90068-9 | eng |
hcfmusp.relation.reference | Canto GD, 2015, SLEEP MED REV, V23, P28, DOI 10.1016/j.smrv.2014.11.004 | eng |
hcfmusp.relation.reference | Cintra F, 2011, CHEST, V139, P246, DOI 10.1378/chest.10-0667 | eng |
hcfmusp.relation.reference | Costa LE, 2015, HEART, V101, P1288, DOI 10.1136/heartjnl-2014-307276 | eng |
hcfmusp.relation.reference | Craig SE, 2012, THORAX, V67, P1090, DOI 10.1136/thoraxjnl-2012-202178 | eng |
hcfmusp.relation.reference | Cuspidi C, 2017, J CLIN HYPERTENS, V19, P713, DOI 10.1111/jch.13023 | eng |
hcfmusp.relation.reference | Freitas IGD, 2015, SLEEP BREATH, V19, P755, DOI 10.1007/s11325-015-1143-9 | eng |
hcfmusp.relation.reference | Deng T, 2016, ANNU REV PATHOL-MECH, V11, P421, DOI 10.1146/annurev-pathol-012615-044359 | eng |
hcfmusp.relation.reference | Drager LF, 2017, CIRCULATION, V136, P1840, DOI 10.1161/CIRCULATIONAHA.117.029400 | eng |
hcfmusp.relation.reference | Drager LF, 2017, SLEEP SCI, V10, P55, DOI 10.5935/1984-0063.20170009 | eng |
hcfmusp.relation.reference | Drager LF, 2015, AM J PHYSIOL-HEART C, V309, pH1101, DOI 10.1152/ajpheart.00094.2015 | eng |
hcfmusp.relation.reference | Drager LF, 2013, J AM COLL CARDIOL, V62, P569, DOI 10.1016/j.jacc.2013.05.045 | eng |
hcfmusp.relation.reference | Fatureto-Borges F, 2018, HYPERTENSION, V72, P399, DOI 10.1161/HYPERTENSIONAHA.118.10825 | eng |
hcfmusp.relation.reference | Feliciano A, 2017, DATA BRIEF, V11, P103, DOI 10.1016/j.dib.2017.01.005 | eng |
hcfmusp.relation.reference | Ferrarini A, 2013, ELECTROPHORESIS, V34, P2873, DOI 10.1002/elps.201300081 | eng |
hcfmusp.relation.reference | FOLLENIUS M, 1991, SLEEP, V14, P211 | eng |
hcfmusp.relation.reference | Freitas LS, 2020, SLEEP BREATH, V24, P1463, DOI 10.1007/s11325-019-02003-1 | eng |
hcfmusp.relation.reference | Genta-Pereira DC, 2018, HYPERTENSION, V72, P979, DOI 10.1161/HYPERTENSIONAHA.118.11525 | eng |
hcfmusp.relation.reference | Geovanini GR, 2016, HEART, V102, P1193, DOI 10.1136/heartjnl-2015-309009 | eng |
hcfmusp.relation.reference | Giampa SQC, 2018, J HUM HYPERTENS, V32, P518, DOI 10.1038/s41371-018-0072-z | eng |
hcfmusp.relation.reference | Gozal D, 2009, AM J RESP CRIT CARE, V180, P1253, DOI 10.1164/rccm.200905-0765OC | eng |
hcfmusp.relation.reference | Griffin JL, 2011, NAT REV CARDIOL, V8, P630, DOI 10.1038/nrcardio.2011.138 | eng |
hcfmusp.relation.reference | Gupta SK, 2010, CIRC-CARDIOVASC GENE, V3, P484, DOI 10.1161/CIRCGENETICS.110.958363 | eng |
hcfmusp.relation.reference | Haight James S J, 2003, Sleep Breath, V7, P53, DOI 10.1007/s11325-003-0053-4 | eng |
hcfmusp.relation.reference | Insenser M, 2013, EXPERT REV PROTEOMIC, V10, P435, DOI 10.1586/14789450.2013.837665 | eng |
hcfmusp.relation.reference | Jenner R, 2017, J CLIN HYPERTENS, V19, P910, DOI 10.1111/jch.13008 | eng |
hcfmusp.relation.reference | Khalyfa A, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01072-2019 | eng |
hcfmusp.relation.reference | Khalyfa A, 2020, SLEEP, V43, DOI 10.1093/sleep/zsz217 | eng |
hcfmusp.relation.reference | Khalyfa A, 2016, SLEEP, V39, P2077, DOI 10.5665/sleep.6302 | eng |
hcfmusp.relation.reference | Khalyfa A, 2016, AM J RESP CRIT CARE, V194, P1116, DOI 10.1164/rccm.201602-0323OC | eng |
hcfmusp.relation.reference | Kheirandish-Gozal L, 2017, CHEST, V151, P500, DOI 10.1016/j.chest.2016.09.026 | eng |
hcfmusp.relation.reference | Kohli M, 2019, SLEEP MED, V64, P92, DOI 10.1016/j.sleep.2019.07.002 | eng |
hcfmusp.relation.reference | Kokturk O, 2006, RESP MED, V100, P536, DOI 10.1016/j.rmed.2005.05.025 | eng |
hcfmusp.relation.reference | Konvalinka A, 2012, CLIN CHEM, V58, P353, DOI 10.1373/clinchem.2011.165969 | eng |
hcfmusp.relation.reference | Kuniyoshi FHS, 2011, CHEST, V140, P1192, DOI 10.1378/chest.10-2625 | eng |
hcfmusp.relation.reference | Lal C, 2019, SLEEP BREATH, V23, P251, DOI 10.1007/s11325-018-1693-8 | eng |
hcfmusp.relation.reference | Lavie L, 2001, CHEST, V120, P900, DOI 10.1378/chest.120.3.900 | eng |
hcfmusp.relation.reference | Lebkuchen A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29727-6 | eng |
hcfmusp.relation.reference | Lee CH, 2016, CIRCULATION, V133, P2008, DOI 10.1161/CIRCULATIONAHA.115.019392 | eng |
hcfmusp.relation.reference | LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y | eng |
hcfmusp.relation.reference | Li K, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000009813 | eng |
hcfmusp.relation.reference | Li RX, 2002, J MOL CATAL A-CHEM, V178, P181, DOI 10.1016/S1381-1169(01)00294-1 | eng |
hcfmusp.relation.reference | Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315 | eng |
hcfmusp.relation.reference | Maeder MT, 2016, CLIN CHIM ACTA, V460, P152, DOI 10.1016/j.cca.2016.06.046 | eng |
hcfmusp.relation.reference | Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7 | eng |
hcfmusp.relation.reference | Marti-Soler H, 2016, LANCET RESP MED, V4, P742, DOI 10.1016/S2213-2600(16)30075-3 | eng |
hcfmusp.relation.reference | Martinez-Garcia MA, 2013, JAMA-J AM MED ASSOC, V310, P2407, DOI 10.1001/jama.2013.281250 | eng |
hcfmusp.relation.reference | Mazzotti DR, 2019, AM J RESP CRIT CARE, V200, P493, DOI 10.1164/rccm.201808-1509OC | eng |
hcfmusp.relation.reference | Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105 | eng |
hcfmusp.relation.reference | Moreno-Pino F, 2019, J CLIN SLEEP MED, V15, P1645, DOI 10.5664/jcsm.8032 | eng |
hcfmusp.relation.reference | Murri M, 2014, CLIN CHIM ACTA, V429, P181, DOI 10.1016/j.cca.2013.12.018 | eng |
hcfmusp.relation.reference | Nordstrom A, 2010, J NEUROIMMUNE PHARM, V5, P4, DOI 10.1007/s11481-009-9156-4 | eng |
hcfmusp.relation.reference | O'Neil SE, 2011, J PROTEOMICS, V75, P192, DOI 10.1016/j.jprot.2011.10.008 | eng |
hcfmusp.relation.reference | OZAKI N, 1986, NEUROPSYCHOBIOLOGY, V16, P88, DOI 10.1159/000118304 | eng |
hcfmusp.relation.reference | Patti GJ, 2012, NAT REV MOL CELL BIO, V13, P263, DOI 10.1038/nrm3314 | eng |
hcfmusp.relation.reference | Peres BU, 2019, SLEEP MED REV, V44, P48, DOI 10.1016/j.smrv.2018.12.004 | eng |
hcfmusp.relation.reference | Perry JC, 2007, RESP PHYSIOL NEUROBI, V156, P250, DOI 10.1016/j.resp.2006.10.004 | eng |
hcfmusp.relation.reference | Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607 | eng |
hcfmusp.relation.reference | Rhee EP, 2012, CLIN CHEM, V58, P139, DOI 10.1373/clinchem.2011.169573 | eng |
hcfmusp.relation.reference | Sanchez-de-la-Torre M, 2015, J AM COLL CARDIOL, V66, P1023, DOI 10.1016/j.jacc.2015.06.1315 | eng |
hcfmusp.relation.reference | Santamaria-Martos F, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49940-1 | eng |
hcfmusp.relation.reference | Seetho IW, 2014, CHRON RESP DIS, V11, P257, DOI 10.1177/1479972314552806 | eng |
hcfmusp.relation.reference | Shukla HD, 2012, PROTEOMICS, V12, P3085, DOI 10.1002/pmic.201100519 | eng |
hcfmusp.relation.reference | Snowden S, 2012, BIOANALYSIS, V4, P2265, DOI [10.4155/BIO.12.218, 10.4155/bio.12.218] | eng |
hcfmusp.relation.reference | Stenlof K, 1996, AM J PHYSIOL-ENDOC M, V271, pE1036 | eng |
hcfmusp.relation.reference | Sutherland JP, 2004, METAB SYNDR RELAT D, V2, P82, DOI 10.1089/met.2004.2.82 | eng |
hcfmusp.relation.reference | Svatikova A, 2004, EUR HEART J, V25, P1325, DOI 10.1016/j.ehj.2004.05.018 | eng |
hcfmusp.relation.reference | Uchoa CHG, 2017, CHEST, V152, P1230, DOI 10.1016/j.chest.2017.08.003 | eng |
hcfmusp.relation.reference | Vasan RS, 2006, CIRCULATION, V113, P2335, DOI 10.1161/CIRCULATIONAHA.104.482570 | eng |
hcfmusp.relation.reference | Verma Mukesh, 2011, Cancers (Basel), V3, P3773, DOI 10.3390/cancers3043773 | eng |
hcfmusp.relation.reference | Waterman CL, 2010, BBA-MOL CELL BIOL L, V1801, P230, DOI 10.1016/j.bbalip.2009.11.004 | eng |
hcfmusp.relation.reference | Xu HJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep30958 | eng |
hcfmusp.relation.reference | Yaggi HK, 2005, NEW ENGL J MED, V353, P2034, DOI 10.1056/NEJMoa043104 | eng |
hcfmusp.relation.reference | Zhang DM, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006429 | eng |
hcfmusp.relation.reference | Zhang HN, 2018, METABOLISM, V85, P97, DOI 10.1016/j.metabol.2018.02.012 | eng |
hcfmusp.relation.reference | Zhao YY, 2013, CLIN CHIM ACTA, V422, P59, DOI 10.1016/j.cca.2013.03.033 | eng |
dc.description.index | MEDLINE | eng |
dc.identifier.eissn | 1873-2615 | |
hcfmusp.citation.scopus | 22 | - |
hcfmusp.scopus.lastupdate | 2024-04-11 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MCM Artigos e Materiais de Revistas Científicas - HC/InCor Artigos e Materiais de Revistas Científicas - LIM/63 Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_LEBKUCHEN_Advances_and_challenges_in_pursuing_biomarkers_for_obstructive_2021.PDF Restricted Access | publishedVersion (English) | 1.44 MB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.